title: A prognostic DNA signature for T1T2 node-negative breast cancer patients.
abstract: Predicting evolution of small node-negative breast carcinoma is a real challenge in clinical practice. The aim of this study was to search whether qualitative or quantitative DNA changes may help to predict metastasis of small node-negative breast carcinoma. Small invasive ductal carcinomas without axillary lymph node involvement (T1T2N0) from 168 patients with either good (111 patients with no event at 5 years after diagnosis) or poor (57 patients with early metastasis) outcome were analyzed with comparative genomic hybridization (CGH) array. A CGH classifier, identifying low- and high-risk groups of metastatic recurrence, was established in a training set of 78 patients, then validated, and compared with clinicopathological parameters in a distinct set of 90 patients. The genomic status of regions located on 2p22.2, 3p23, and 8q21-24 and the number of segmental alterations were defined in the training set to classify tumors into low- or high-risk groups. In the validation set, in addition to estrogen receptors and grade, this CGH classifier provided significant prognostic information in multivariate analysis (odds ratio, 3.34; 95% confidence interval 1.01-11.02; P = 4.78 × 10(-2), Wald test). This study shows that tumor DNA contains important prognostic information that may help to predict metastasis in T1T2N0 tumors of the breast.
authors.affiliation: Department of Translational Research, Institut Curie, 26 rue d’Ulm, Paris, France.
authors.forename: Eléonore
authors.initials: E
authors.lastname: Gravier
authors.forename: Gaëlle
authors.initials: G
authors.lastname: Pierron
authors.forename: Anne
authors.initials: A
authors.lastname: Vincent-Salomon
authors.forename: Nadège
authors.initials: N
authors.lastname: Gruel
authors.forename: Virginie
authors.initials: V
authors.lastname: Raynal
authors.forename: Alexia
authors.initials: A
authors.lastname: Savignoni
authors.forename: Yann
authors.initials: Y
authors.lastname: De Rycke
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Pierga
authors.forename: Carlo
authors.initials: C
authors.lastname: Lucchesi
authors.forename: Fabien
authors.initials: F
authors.lastname: Reyal
authors.forename: Alain
authors.initials: A
authors.lastname: Fourquet
authors.forename: Sergio
authors.initials: S
authors.lastname: Roman-Roman
authors.forename: François
authors.initials: F
authors.lastname: Radvanyi
authors.forename: Xavier
authors.initials: X
authors.lastname: Sastre-Garau
authors.forename: Bernard
authors.initials: B
authors.lastname: Asselain
authors.forename: Olivier
authors.initials: O
authors.lastname: Delattre
mesh_terms: D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology*; D018270:Carcinoma, Ductal, Breast / Q000235:genetics* / Q000473:pathology* / Q000556:secondary; D016022:Case-Control Studies; D002889:Chromosomes, Human, Pair 2 / Q000235:genetics; D002893:Chromosomes, Human, Pair 3 / Q000235:genetics; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics; D055028:Comparative Genomic Hybridization; D020732:Cytogenetic Analysis; D004273:DNA, Neoplasm / Q000235:genetics*; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology*; D008207:Lymphatic Metastasis; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D017063:Outcome Assessment, Health Care; D011379:Prognosis; D011960:Receptors, Estrogen; D018570:Risk Assessment
chemical_list: D004273:DNA, Neoplasm; D011960:Receptors, Estrogen